Corrigendum to "The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials" [Schizophrenia Research 105 (2008) 208-215] (DOI:10.1016/j.schres.2008.06.018);The efficacy of aripiprazole in the treatment of multiple symptom domains in patients with acute schizophrenia: A pooled analysis of data from the pivotal trials

Schizophrenia Research

Volumn 105, Issue 1-3, 2008, Pages 208-215

  Kane, John M ^a   Assunção Talbott, Sheila ^b   Eudicone, James M ^b   Pikalov, Andrei ^c   Whitehead, Richard ^c   Crandall, David T ^b  

^a ZUCKER HILLSIDE HOSPITAL   (United States)

^b BRISTOL MYERS SQUIBB   (United States)

^c OTSUKA PHARMACEUTICAL DEVELOPMENT AND COMMERCIALIZATION INC   (United States)

Author keywords

Aripiprazole; Item analysis; Schizophrenia

Indexed keywords

ARIPIPRAZOLE; HALOPERIDOL; PLACEBO;

ACUTE DISEASE; ANXIETY DISORDER; ARTICLE; ATTENTION DISTURBANCE; BLUNTED AFFECT; CLINICAL TRIAL; DECISION MAKING; DELUSION; DEPRESSION; DISEASE EXACERBATION; DISORIENTATION; DRUG EFFICACY; EXCITEMENT; GESTURE; GRANDIOSE DELUSION; GUILT; HALLUCINATION; HOSTILITY; HUMAN; IMPULSIVENESS; MENTAL STRESS; MOTOR RETARDATION; PARANOIA; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; PSYCHOSOCIAL WITHDRAWAL; SCHIZOAFFECTIVE PSYCHOSIS; SCHIZOPHRENIA; SOCIAL AVOIDANCE BEHAVIOR; STATISTICAL SIGNIFICANCE; THINKING IMPAIRMENT; THOUGHT DISORDER; UNSPECIFIED SIDE EFFECT;

EID: 52949130604     PISSN: 09209964     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.schres.2008.10.012     Document Type: Erratum

References (28)

1. Bowie C.R., Reichenberg A., Patterson T.L., Heaton R.K., and Harvey P.D. Determinants of real-world functional performance in schizophrenia subjects: correlations with cognition, functional capacity, and symptoms. Am. J. Psychiatry 163 3 (2006) 418-425
2. Burris K.D., Molski T.F., Xu C., Ryan E., Tottori K., Kikuchi T., Yocca F.D., and Molinoff P.B. Aripiprazole, a novel antipsychotic, is a high-affinity partial agonist at human dopamine D2 receptors. J. Pharmacol. Exp. Ther. 302 1 (2002) 381-389
3. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. (1988), L. Erlbaum Associates, Hillsdale, N.J.
4. Daniel D.G., Saha A.R., Ingenito G., Carson W.H., and Dunbar G. Aripiprazole, a novel antipsychotic: overview of a phase 2 study result. Int. J. Neuropsychopharmacol. 3 Suppl. 1 (2000) S157
5. Day J.C., Bentall R.P., Roberts C., Randall F., Rogers A., Cattell D., Healy D., Rae P., and Power C. Attitudes toward antipsychotic medication: the impact of clinical variables and relationships with health professionals. Arch. Gen. Psychiatry 62 7 (2005) 717-724
6. Farah A. Atypicality of atypical antipsychotics. Prim. Care Companion J. Clin. Psychiatry 7 6 (2005) 268-274
7. Frank A.F., and Gunderson J.G. The role of the therapeutic alliance in the treatment of schizophrenia. Relationship to course and outcome. Arch. Gen. Psychiatry 47 3 (1990) 228-236
8. Gray J., Roth B., Marder S., West B., Lau G., Pultz J., Pikalov A., Marcus R., Gutierrez-Esteinou R., and Crandall D. Molecular targets for treating cognitive dysfunction in schizophrenia. Schizophr. Bull. 33 5 (2007) 1100-1119
9. Jin H., Zisook S., Palmer B.W., Patterson T.L., Heaton R.K., and Jeste D.V. Association of depressive symptoms with worse functioning in schizophrenia: a study in older outpatients. J. Clin. Psychiatry 62 10 (2001) 797-803
10. Jordan S., Koprivica V., Dunn R., Tottori K., Kikuchi T., and Altar C.A. In vivo effects of aripiprazole on cortical and striatal dopaminergic and serotonergic function. Eur. J. Pharmacol. 483 1 (2004) 45-53
11. Kane J.M., Carson W.H., Saha A.R., McQuade R.D., Ingenito G.G., Zimbroff D.L., and Ali M.W. Efficacy and safety of aripiprazole and haloperidol versus placebo in patients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 63 9 (2002) 763-771
12. Karow A., Moritz S., Lambert M., Schoder S., and Krausz M. PANSS syndromes and quality of life in schizophrenia. Psychopathology 38 6 (2005) 320-326
13. Kay S.R., Fiszbein A., and Opler L.A. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr. Bull. 13 2 (1987) 261-276
14. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., and Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50 11 (2001) 884-897
15. Lindenmayer J.P., and Khan A. Pharmacological treatment strategies for schizophrenia. Expert. Rev. Neurother. 4 4 (2004) 705-723
16. Marder S.R., McQuade R.D., Stock E., Kaplita S., Marcus R., Safferman A.Z., Saha A., Ali M., and Iwamoto T. Aripiprazole in the treatment of schizophrenia: safety and tolerability in short-term, placebo-controlled trials. Schizophr. Res. 61 2-3 (2003) 123-136
17. Markou P. Depression in schizophrenia: a descriptive study. Aust. N. Z. J. Psychiatry 30 3 (1996) 354-357
18. McEvoy J.P., Daniel D.G., Carson Jr. W.H., McQuade R.D., and Marcus R.N. A randomized, double-blind, placebo-controlled, study of the efficacy and safety of aripiprazole 10, 15 or 20 mg/day for the treatment of patients with acute exacerbations of schizophrenia. J. Psychiatr. Res. 41 11 (2007) 895-905
19. Petrie J.L., Saha A.R., and McEvoy J.P. Aripiprazole, a new antipsychotic: phase II clinical trial results. Eur. Neuropsychopharmacol. 7 Suppl 2 (1997) S227
20. Potkin S.G., Saha A.R., Kujawa M.J., Carson W.H., Ali M., Stock E., Stringfellow J., Ingenito G., and Marder S.R. Aripiprazole, an antipsychotic with a novel mechanism of action, and risperidone vs placebo in patients with schizophrenia and schizoaffective disorder. Arch. Gen. Psychiatry 60 7 (2003) 681-690
21. Roy A. Depression, attempted suicide, and suicide in patients with chronic schizophrenia. Psychiatr. Clin. North Am. 9 1 (1986) 193-206
22. Roy A., Thompson R., and Kennedy S. Depression in chronic schizophrenia. Br. J. Psychiatry 142 (1983) 465-470
23. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 2: illustrating their mechanism of action. J. Clin. Psychiatry 62 12 (2001) 923-924
24. Stahl S.M. Dopamine system stabilizers, aripiprazole, and the next generation of antipsychotics, part 1, "Goldilocks" actions at dopamine receptors. J. Clin. Psychiatry 62 11 (2001) 841-842
25. Sumiyoshi T., Park S., Jayathilake K., Roy A., Ertugrul A., and Meltzer H. Effect of buspirone, a serotonin1A partial agonist, on cognitive function in schizophrenia: a randomized, double-blind, placebo-controlled study. Schizophr. Res. 95 1-3 (2007) 158-168
26. Tadori Y., Miwa T., Tottori K., Burris K.D., Stark A., Mori T., and Kikuchi T. Aripiprazole's low intrinsic activities at human dopamine D2L and D2S receptors render it a unique antipsychotic. Eur. J. Pharmacol. 515 1-3 (2005) 10-19
27. Wetherell J.L., Palmer B.W., Thorp S.R., Patterson T.L., Golshan S., and Jeste D.V. Anxiety symptoms and quality of life in middle-aged and older outpatients with schizophrenia and schizoaffective disorder. J. Clin. Psychiatry 64 12 (2003) 1476-1482
28. Yatham L., Goldstein J., Vieta E., Bowden C., Grunze H., Post R., Suppes T., and Calabrese J. Atypical antipsychotics in bipolar depression: potential mechanisms of action. J. Clin. Psychiatry 66 Suppl 5 (2005) 40-48